Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs

N. Esther Babady, Matthew R. England, Kristen L. Jurcic Smith, Taojun He, Dona Saumya Wijetunge, Yi Wei Tang, Robin R. Chamberland, Marilyn Menegus, Ella M. Swierkosz, Robert C. Jerris, Wallace Greene

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The performance of the new ePlex Respiratory Pathogen (RP) panel (GenMark Diagnostics) for the simultaneous detection of 19 viruses (influenza A virus; influenza A H1 virus; influenza A 2009 H1 virus; influenza A H3 virus; influenza B virus; adenovirus; coronaviruses [HKU1, OC43, NL63, and 229E]; human rhinovirus/enterovirus; human metapneumovirus; parainfluenza viruses 1, 2, 3, and 4; and respiratory syncytial virus [RSV] [RSV subtype A and RSV subtype B]) and 2 bacteria (Mycoplasma pneumoniae and Chlamydia pneumoniae) was evaluated. Prospectively and retrospectively collected nasopharyngeal swab (NPS) specimens (n = 2,908) were evaluated by using the ePlex RP panel, with the bioMérieux/BioFire FilmArray Respiratory Panel (BioFire RP) as the comparator method. Discordance analysis was performed by using target-specific PCRs and bidirectional sequencing. The reproducibility of the assay was evaluated by using reproducibility panels comprised of 6 pathogens. The overall agreement between the ePlex RP and BioFire RP results was >95% for all targets. Positive percent agreement with the BioFire RP result for viruses ranged from 85.1% (95% confidence interval [CI], 80.2% to 88.9%) to 95.1% (95% CI, 89.0% to 97.9%), while negative percent agreement values ranged from 99.5% (95% CI, 99.1% to 99.7%) to 99.8% (95% CI, 99.5% to 99.9%). Additional testing of discordant targets (12%; 349/2,908) confirmed the results of ePlex RP for 38% (131/349) of samples tested. Reproducibility was 100% for all targets tested, with the exception of adenovirus, for which reproducibilities were 91.6% at low virus concentrations and 100% at moderate virus concentrations. The ePlex RP panel offers a new, rapid, and sensitive "sample-to-answer" multiplex panel for the detection of the most common viral and bacterial respiratory pathogens.

Original languageEnglish (US)
JournalJournal of clinical microbiology
Volume56
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Respiratory System
Viruses
Respiratory Syncytial Viruses
Influenza A virus
Confidence Intervals
Adenoviridae
Metapneumovirus
Influenza B virus
Paramyxoviridae Infections
Rhinovirus
Chlamydophila pneumoniae
Mycoplasma pneumoniae
Coronavirus
Enterovirus
Human Influenza
Bacteria
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)

Cite this

Babady, N. Esther ; England, Matthew R. ; Jurcic Smith, Kristen L. ; He, Taojun ; Wijetunge, Dona Saumya ; Tang, Yi Wei ; Chamberland, Robin R. ; Menegus, Marilyn ; Swierkosz, Ella M. ; Jerris, Robert C. ; Greene, Wallace. / Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs. In: Journal of clinical microbiology. 2018 ; Vol. 56, No. 2.
@article{cafbb525ad6c46be973138ebcad4ea76,
title = "Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs",
abstract = "The performance of the new ePlex Respiratory Pathogen (RP) panel (GenMark Diagnostics) for the simultaneous detection of 19 viruses (influenza A virus; influenza A H1 virus; influenza A 2009 H1 virus; influenza A H3 virus; influenza B virus; adenovirus; coronaviruses [HKU1, OC43, NL63, and 229E]; human rhinovirus/enterovirus; human metapneumovirus; parainfluenza viruses 1, 2, 3, and 4; and respiratory syncytial virus [RSV] [RSV subtype A and RSV subtype B]) and 2 bacteria (Mycoplasma pneumoniae and Chlamydia pneumoniae) was evaluated. Prospectively and retrospectively collected nasopharyngeal swab (NPS) specimens (n = 2,908) were evaluated by using the ePlex RP panel, with the bioM{\'e}rieux/BioFire FilmArray Respiratory Panel (BioFire RP) as the comparator method. Discordance analysis was performed by using target-specific PCRs and bidirectional sequencing. The reproducibility of the assay was evaluated by using reproducibility panels comprised of 6 pathogens. The overall agreement between the ePlex RP and BioFire RP results was >95{\%} for all targets. Positive percent agreement with the BioFire RP result for viruses ranged from 85.1{\%} (95{\%} confidence interval [CI], 80.2{\%} to 88.9{\%}) to 95.1{\%} (95{\%} CI, 89.0{\%} to 97.9{\%}), while negative percent agreement values ranged from 99.5{\%} (95{\%} CI, 99.1{\%} to 99.7{\%}) to 99.8{\%} (95{\%} CI, 99.5{\%} to 99.9{\%}). Additional testing of discordant targets (12{\%}; 349/2,908) confirmed the results of ePlex RP for 38{\%} (131/349) of samples tested. Reproducibility was 100{\%} for all targets tested, with the exception of adenovirus, for which reproducibilities were 91.6{\%} at low virus concentrations and 100{\%} at moderate virus concentrations. The ePlex RP panel offers a new, rapid, and sensitive {"}sample-to-answer{"} multiplex panel for the detection of the most common viral and bacterial respiratory pathogens.",
author = "Babady, {N. Esther} and England, {Matthew R.} and {Jurcic Smith}, {Kristen L.} and Taojun He and Wijetunge, {Dona Saumya} and Tang, {Yi Wei} and Chamberland, {Robin R.} and Marilyn Menegus and Swierkosz, {Ella M.} and Jerris, {Robert C.} and Wallace Greene",
year = "2018",
month = "2",
day = "1",
doi = "10.1128/JCM.01658-17",
language = "English (US)",
volume = "56",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "2",

}

Babady, NE, England, MR, Jurcic Smith, KL, He, T, Wijetunge, DS, Tang, YW, Chamberland, RR, Menegus, M, Swierkosz, EM, Jerris, RC & Greene, W 2018, 'Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs', Journal of clinical microbiology, vol. 56, no. 2. https://doi.org/10.1128/JCM.01658-17

Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs. / Babady, N. Esther; England, Matthew R.; Jurcic Smith, Kristen L.; He, Taojun; Wijetunge, Dona Saumya; Tang, Yi Wei; Chamberland, Robin R.; Menegus, Marilyn; Swierkosz, Ella M.; Jerris, Robert C.; Greene, Wallace.

In: Journal of clinical microbiology, Vol. 56, No. 2, 01.02.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs

AU - Babady, N. Esther

AU - England, Matthew R.

AU - Jurcic Smith, Kristen L.

AU - He, Taojun

AU - Wijetunge, Dona Saumya

AU - Tang, Yi Wei

AU - Chamberland, Robin R.

AU - Menegus, Marilyn

AU - Swierkosz, Ella M.

AU - Jerris, Robert C.

AU - Greene, Wallace

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The performance of the new ePlex Respiratory Pathogen (RP) panel (GenMark Diagnostics) for the simultaneous detection of 19 viruses (influenza A virus; influenza A H1 virus; influenza A 2009 H1 virus; influenza A H3 virus; influenza B virus; adenovirus; coronaviruses [HKU1, OC43, NL63, and 229E]; human rhinovirus/enterovirus; human metapneumovirus; parainfluenza viruses 1, 2, 3, and 4; and respiratory syncytial virus [RSV] [RSV subtype A and RSV subtype B]) and 2 bacteria (Mycoplasma pneumoniae and Chlamydia pneumoniae) was evaluated. Prospectively and retrospectively collected nasopharyngeal swab (NPS) specimens (n = 2,908) were evaluated by using the ePlex RP panel, with the bioMérieux/BioFire FilmArray Respiratory Panel (BioFire RP) as the comparator method. Discordance analysis was performed by using target-specific PCRs and bidirectional sequencing. The reproducibility of the assay was evaluated by using reproducibility panels comprised of 6 pathogens. The overall agreement between the ePlex RP and BioFire RP results was >95% for all targets. Positive percent agreement with the BioFire RP result for viruses ranged from 85.1% (95% confidence interval [CI], 80.2% to 88.9%) to 95.1% (95% CI, 89.0% to 97.9%), while negative percent agreement values ranged from 99.5% (95% CI, 99.1% to 99.7%) to 99.8% (95% CI, 99.5% to 99.9%). Additional testing of discordant targets (12%; 349/2,908) confirmed the results of ePlex RP for 38% (131/349) of samples tested. Reproducibility was 100% for all targets tested, with the exception of adenovirus, for which reproducibilities were 91.6% at low virus concentrations and 100% at moderate virus concentrations. The ePlex RP panel offers a new, rapid, and sensitive "sample-to-answer" multiplex panel for the detection of the most common viral and bacterial respiratory pathogens.

AB - The performance of the new ePlex Respiratory Pathogen (RP) panel (GenMark Diagnostics) for the simultaneous detection of 19 viruses (influenza A virus; influenza A H1 virus; influenza A 2009 H1 virus; influenza A H3 virus; influenza B virus; adenovirus; coronaviruses [HKU1, OC43, NL63, and 229E]; human rhinovirus/enterovirus; human metapneumovirus; parainfluenza viruses 1, 2, 3, and 4; and respiratory syncytial virus [RSV] [RSV subtype A and RSV subtype B]) and 2 bacteria (Mycoplasma pneumoniae and Chlamydia pneumoniae) was evaluated. Prospectively and retrospectively collected nasopharyngeal swab (NPS) specimens (n = 2,908) were evaluated by using the ePlex RP panel, with the bioMérieux/BioFire FilmArray Respiratory Panel (BioFire RP) as the comparator method. Discordance analysis was performed by using target-specific PCRs and bidirectional sequencing. The reproducibility of the assay was evaluated by using reproducibility panels comprised of 6 pathogens. The overall agreement between the ePlex RP and BioFire RP results was >95% for all targets. Positive percent agreement with the BioFire RP result for viruses ranged from 85.1% (95% confidence interval [CI], 80.2% to 88.9%) to 95.1% (95% CI, 89.0% to 97.9%), while negative percent agreement values ranged from 99.5% (95% CI, 99.1% to 99.7%) to 99.8% (95% CI, 99.5% to 99.9%). Additional testing of discordant targets (12%; 349/2,908) confirmed the results of ePlex RP for 38% (131/349) of samples tested. Reproducibility was 100% for all targets tested, with the exception of adenovirus, for which reproducibilities were 91.6% at low virus concentrations and 100% at moderate virus concentrations. The ePlex RP panel offers a new, rapid, and sensitive "sample-to-answer" multiplex panel for the detection of the most common viral and bacterial respiratory pathogens.

UR - http://www.scopus.com/inward/record.url?scp=85066862593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066862593&partnerID=8YFLogxK

U2 - 10.1128/JCM.01658-17

DO - 10.1128/JCM.01658-17

M3 - Article

C2 - 29212701

AN - SCOPUS:85066862593

VL - 56

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 2

ER -